[1] GRAM was founded in 2010 by Van Andel Institute and Grand Valley State University.

[1] In 2017, Arlington Capital Partners, a private equity firm in Washington, D.C. took a majority ownership stake in GRAM.

[5] In June 2020, GRAM finished a $60 million expansion to install another fill-finish injectables facility with the plan to market it to U.S.

[4] The 61,500-square-foot facility included in that expansion tripled GRAM's manufacturing footprint to more than 100,000 square feet of production space.

[6] In August 2020, BARDA awarded GRAM a one-year, $160 million contract to provide fill and finish services for vaccines in response to the coronavirus pandemic.